VYNE shares surge 13.10% premarket after Q3 loss narrows, revenue beats estimates, and cost reductions extend cash runway into 2027.

VYNE Therapeutics Inc. (VYNE) surged 13.10% in premarket trading following its Q3 2025 earnings report and business update. The company exceeded revenue estimates by 12.67% with $0.2 million in revenue, while its net loss narrowed to $7.3 million ($0.17/share), reflecting a 48.7% year-over-year reduction in R&D expenses. Management highlighted a strategic review to evaluate partnerships, asset sales, or other value-creating opportunities, alongside cost-cutting measures that extended its cash runway into the first half of 2027. Additionally, a 12-week non-clinical toxicology study for VYN202 was initiated to address an FDA partial hold on male clinical trials, signaling progress in resolving regulatory hurdles. These developments—combined with improved earnings surprises and reduced operational costs—likely drove the sharp premarket rise amid ongoing strategic and clinical catalysts.